September 14, 2026

FOR IMMEDIATE RELEASE

Company Name: Premier Anti-Aging Co., Ltd.
(Securities Code: 4934 Tokyo Stock Exchange)
Representative: Kiyoshi Matsuura
President and Representative Director
Inquiries: Yuka Uehara
Executive Officer of Corporate Division
Phone: +81-3-3502-2020

Notice concerning difference between consolidated earnings forecasts and actual results for the fiscal year ended July 31, 2026

Premier Anti-Aging Co., Ltd. ("the Company") announces that there is a difference between consolidated earnings forecasts for the fiscal year ended July 31, 2026 announced on June 12, 2026, and the actual results announced today as follows.

1. Difference between consolidated earnings forecasts for the fiscal year ended July 31, 2026 (August 1, 2025 to July 31, 2026) and actual results

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previous Forecast (A) (Announced on June 12, 2026)	13,500	300	300	300	34.40 yen
Actual Results (B)	13,883	494	602	364	41.77 yen
Difference (B－A)	383	194	302	64	
Rate of Change (%)	2.8	64.9	100.9	21.4	
(Reference) Previous Actual Results (Fiscal Year ended July 31, 2025)	16,160	617	599	471	54.10 yen

2. Rational for difference

For the fiscal year ended July 31, 2026, sales in the recovery business proceeded according to projection, driven by the expansion of the recovery market, with particularly solid performance in offline channels such as department stores. On the other hand, the business environment surrounding the anti-aging business remained challenging, and sales in the mail order business fell short of the previous year's figures, as the recovery of new customer acquisition took longer than anticipated. As a result, company-wide sales ended up being almost exactly in line with the revised projection.

On the profit and loss side, we executed investments almost exactly as projected during the fourth quarter. This included continued investment in testing new customer acquisition methods for the anti-aging business, as well as advertising and promotional investments for “DUO Cleanse Serum Peel & Boost,” which is a cleansing serum from DUO new line and for “DUO Poreless,” which addresses adult pore concerns at their root. In addition, by further promoting appropriate cost management, primarily focused on reducing fixed costs throughout the Company, operating profit ended up exceeding the projection. Furthermore, while ordinary profit exceeded the projection primarily due to the recording of foreign exchange gains, profit attributable to owners of parent differed as described above because the Company decided to consolidate its sales system in China into a more efficient and high-growth cross-border e-commerce platform and to dissolve and liquidate its local subsidiary, resulting in the recording of restructuring costs as an extraordinary loss.